E. V. D. Spek

Targeting the mevalonate pathway in multiple myeloma

E. V. D. Spek, E. Spek, 2010 .

n ew developments in the treatment of patients with multiple myeloma

M. Minnema, E. V. D. Spek, E. Spek, 2010 .

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

P. Sonneveld, A. Bloem, H. Lokhorst, 2013 .

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

P. Sonneveld, A. Waage, N. Abildgaard, 2018, Haematologica.